Europe Pays Price for Trump’s Pharma Rules

This article discusses the impact of a US presidential decree, issued by Donald Trump, on the European pharmaceutical market. The decree, known as the ‘most favored nation’ clause, has led to increased costs for European companies. This situation highlights the effects of US trade policies on the EU’s pharmaceutical industry.

Summarized from the sources above. Read the originals for the full story.